The anaplastic lymphoma kinase (ALK) gene is a member of the insulin receptor superfamily and it has been linked with more than twenty distinct chimera that include established drivers of several human cancers. Non-small-cell lung carcinoma (NSCLC) is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. The market is witnessing strong growth due to high awareness among the population through government initiatives. Furthermore, the drugs for NSCLC are given swift approvals by regulatory bodies and fundings for research. This has led to a new generation of drugs being introduced in the NSCLC market. The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, anaplastic lymphoma kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors.
Global Anaplastic Lymphoma Kinase Inhibitors Market: Dynamics
Growth of Bio-pharmaceutical Industries and Increasing Strategic Collaborations Boosting Market
Increase in number of strategic collaborations between manufacturers and research institutes along with rapidly growing health care and pharmaceutical industries in developed and developing economies are some factors that are anticipated to assist the global anaplastic lymphoma kinase inhibitors market during the forecast period.
To Know the Segments Analyzed in the Anaplastic Lymphoma Kinase Inhibitors Market Report, Ask for a Brochure here
In 2017, Novartis AG entered into strategic agreement with Wyss Institute at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for immuno-oncology therapies.
Increase in Health Care Expenditure Boosting Market
Emerging economics such as India, China, Brazil, Malaysia, and other emerging countries in developing regions such as Asia Pacific, Middle East & Africa, and Latin America offer numerous opportunities in health care sector. Increased government expenditure in health care segment is likely to pace up the expansion of anaplastic lymphoma kinase inhibitors market during the forecast period. For instance, according to the Union Budget 2017-18, in India, the total health care expenditure was increased from 1.97% to 2.27% of total Union Budget.
Increasing Prevalence of NSCLC
Increase in number of patients throughout the world in developing as well as developed economies is anticipated to increase the demand for therapeutics and is expected to drive the global anaplastic lymphoma kinase inhibitors market during the forecast period. For instance, in 2018, approximately 2.1 million new cases of lung cancer were diagnosed across the globe. Lung cancer records the highest mortality rate among developing countries compared to all type of cancers, with developed regions such as North America and Europe ensuring the highest rates.
Global Anaplastic Lymphoma Kinase Inhibitors Market: Competitive Landscape
Major players operating in the global anaplastic lymphoma kinase inhibitors market include F. Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG, Oncoethix GmbH, Pfizer, Inc., and Takeda Pharmaceutical Co., Ltd.
To Know More about TMRs Unique Offerings for Anaplastic Lymphoma Kinase Inhibitors Market, Request a Custom Report here
Hoffman-La Roche Ltd.
Hoffmann-La Roche Ltd. (Roche) is a leading global health care and biotech company that engages in development and marketing of pharmaceuticals, biopharmaceuticals, and In Vitro Diagnostic (IVD) devices & consumables. The company operates through two divisions: Pharmaceuticals and Diagnostics. Its pharmaceuticals business segment provides therapies in the field of oncology, immunology, neuroscience, ophthalmology, infectious diseases, and others. Roche, which also offers diagnostic solutions for oncology and other chronic diseases, has built an expertise in cancer biomarker identification and biological drugs. This has boosted the company’s oncology portfolio.
Pfizer Inc. is a leading biopharmaceutical company that is focused on discovery, development, manufacturing, and commercialization of health care products. Its portfolio includes consumer health care products, vaccines, and medicines. Pfizer operates through two key business segments: Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). Under the Innovative Health segment, the company offers branded oncology and other therapy drugs, while it offers biosimilars for oncology and other indications under the Essential Health segment. Pfizer offers oncology drugs across therapy lines, such as antibody drug conjugate, monoclonal antibodies, and kinase inhibitors.
Global Anaplastic Lymphoma Kinase Inhibitors Market: Segmentation
The global anaplastic lymphoma kinase inhibitors market can be segmented based on:
In terms of type, the anaplastic lymphoma kinase inhibitors market can be classified into:
- Second-generation ALK inhibitors
- First-generation ALK inhibitors
- Third-generation ALK inhibitors
In terms of region, the global anaplastic lymphoma kinase inhibitors market can be segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East & Africa (MEA)
North America accounted for the dominant share of the global anaplastic lymphoma kinase inhibitors market in 2018 owing to the presence of modern health care infrastructure and an efficient U.S. government system. However, Asia Pacific is expected to expand at the highest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and increasing number of government projects related to lung, cancer and their respective interventions would boost the market in APAC during the forecast period.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.